154 related articles for article (PubMed ID: 34158265)
1. IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.
Lawless S; Sbianchi G; Morris C; Iacobelli S; Bosman P; Blaise D; Reményi P; Byrne JL; Mayer J; Apperley J; Lund J; Kobbe G; Schaap N; Isaksson C; Lenhoff S; Basak G; Touzeau C; Wilson KMO; González Muñiz S; Scheid C; Browne P; Anagnostopoulos A; Rambaldi A; Jantunen E; Kröger N; Schönland S; Yakoub-Agha I; Garderet L
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):686-693. PubMed ID: 34158265
[TBL] [Abstract][Full Text] [Related]
2. The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes.
Sharma M; Qureshi SR; Champlin RE; Popat U; Giralt S; Qazilbash MH
Am J Hematol; 2010 Jul; 85(7):502-4. PubMed ID: 20575022
[TBL] [Abstract][Full Text] [Related]
3. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study.
Reece DE; Vesole DH; Shrestha S; Zhang MJ; Pérez WS; Dispenzieri A; Milone GA; Abidi M; Atkins H; Bashey A; Bredeson CN; Boza WB; Freytes CO; Gale RP; Gajewski JL; Gibson J; Hale GA; Kumar S; Kyle RA; Lazarus HM; McCarthy PL; Pavlovsky S; Roy V; Weisdorf DJ; Wiernik PH; Hari PN
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):458-63. PubMed ID: 21156462
[TBL] [Abstract][Full Text] [Related]
4. Melphalan 140 mg/m
Auner HW; Iacobelli S; Sbianchi G; Knol-Bout C; Blaise D; Russell NH; Apperley JF; Pohlreich D; Browne PV; Kobbe G; Isaksson C; Lenhoff S; Scheid C; Touzeau C; Jantunen E; Anagnostopoulos A; Yakoub-Agha I; Tanase A; Schaap N; Wiktor-Jedrzejczak W; Krejci M; Schönland SO; Morris C; Garderet L; Kröger N
Haematologica; 2018 Mar; 103(3):514-521. PubMed ID: 29217776
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and outcome of autologous transplantation in rare myelomas.
Morris C; Drake M; Apperley J; Iacobelli S; van Biezen A; Bjorkstrand B; Goldschmidt H; Harousseau JL; Morgan G; de Witte T; Niederwieser D; Gahrton G;
Haematologica; 2010 Dec; 95(12):2126-33. PubMed ID: 20971818
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Morris C; Iacobelli S; Gahrton G; van Biezen A; Drake M; Garderet L; Potter M; Schattenberg AV; Cornelissen JJ; Hamladji RM; Martelli M; Petersen E; Rovira M; Bandini G; Kroger N; de Witte T
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1054-8. PubMed ID: 25708221
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
[TBL] [Abstract][Full Text] [Related]
9. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
10. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.
Gahrton G; Iacobelli S; Björkstrand B; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Carella AM; Beksac M; Bosi A; Milone G; Corradini P; Schönland S; Friberg K; van Biezen A; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Garderet L; Kröger N;
Blood; 2013 Jun; 121(25):5055-63. PubMed ID: 23482933
[TBL] [Abstract][Full Text] [Related]
11. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
12. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; Alegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G
Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685
[TBL] [Abstract][Full Text] [Related]
13. The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.
Jaglowski SM; Ruppert AS; Hofmeister CC; Elder P; Blum W; Klisovic R; Vasu S; Penza S; Efebera YA; Benson DM; Devine SM; Andritsos LA
Bone Marrow Transplant; 2014 Oct; 49(10):1323-9. PubMed ID: 25068419
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
15. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
16. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.
Alegre A; Díaz-Mediavilla J; San-Miguel J; Martínez R; García Laraña J; Sureda A; Lahuerta JJ; Morales D; Bladé J; Caballero D; De la Rubia J; Escudero A; Díez-Martín JL; Hernández-Navarro F; Rifón J; Odriozola J; Brunet S; De la Serna J; Besalduch J; Vidal MJ; Solano C; Leon A; Sánchez JJ; Martínez-Chamorro C; Fernández-Rañada JM
Bone Marrow Transplant; 1998 Jan; 21(2):133-40. PubMed ID: 9489629
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea.
Kang J; Hong JY; Yoon DH; Kim S; Lee KM; Park JS; Park CJ; Min WK; Seo EJ; Jang S; Suh C
Acta Haematol; 2018; 139(3):185-192. PubMed ID: 29635247
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years.
Bashir Q; Chamoun K; Milton DR; Khan M; Ahmed S; Mehta R; Popat UR; Kebriaei P; Nieto Y; Oran B; Ciurea SO; Hosing C; Khouri I; Patel K; Manasanch EE; Lee HC; Orlowski RZ; Champlin RE; Qazilbash MH
Leuk Lymphoma; 2019 Dec; 60(14):3536-3543. PubMed ID: 31282244
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
Micallef IN; Stiff PJ; Nademanee AP; Maziarz RT; Horwitz ME; Stadtmauer EA; Kaufman JL; McCarty JM; Vargo R; Cheverton PD; Struijs M; Bolwell B; DiPersio JF
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1187-1195. PubMed ID: 29410180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
